Introduction: Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key
features of symptomatic chronic obstructive pulmonary disease (COPD). We assessed the effects
of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on
exercise tolerance in patients with moderate to severe COPD.